Overexpression of matrix metalloproteinase-7 and -9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome
- PMID: 21764478
- DOI: 10.1016/j.lungcan.2011.06.010
Overexpression of matrix metalloproteinase-7 and -9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome
Abstract
Background: Matrix metalloproteinases (MMPs) are considered important players in angiogenesis and cancer progression. Several drugs developed for targeting MMPs have until now been without clinical efficacy. As both malignant cells and cells of the surrounding stroma contribute to tumor growth, we have explored the impact of MMP-2, -7 and -9 expression in both the tumor and stromal compartment of non-small-cell lung cancers (NSCLC).
Patients and methods: From 335 unselected stage I to IIIA NSCLC carcinomas, duplicate tumor and tumor-associated stromal cores were collected in tissue microarrays (TMAs). Immunohistochemistry was used to detect the expression of MMP-2, -7 and -9 in tumor and stromal cells.
Results: In univariate analyses, high tumor cell MMP-7 expression (P=0.029) and high stromal MMP-9 expression (P=0.001) were positive prognostic factors. In the multivariate analysis, high tumor cell MMP-7 expression (HR 1.58, CI 1.08-2.32, P=0.020) and high stromal MMP-9 expression (HR 1.92, CI 1.25-2.96, P=0.003) were independent positive prognostic factors for disease-specific survival.
Conclusion: High levels of MMP-7 in tumor cells and high levels of MMP-9 in tumor associated stroma were independent positive prognostic factors in NSCLC patients.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer.Ai Zheng. 2009 Jan;28(1):60-3. Epub 2009 Jan 16. Ai Zheng. 2009. PMID: 19448419
-
[Prognostic impact of matrix metalloproteinases 2,9, and 11 in stromal cells stage I non-small cell lung cancer].Cas Lek Cesk. 2007;146(1):45-7. Cas Lek Cesk. 2007. PMID: 17310584 Czech.
-
Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.Lung Cancer. 2006 Jun;52(3):349-57. doi: 10.1016/j.lungcan.2006.01.011. Epub 2006 Mar 29. Lung Cancer. 2006. PMID: 16569461 Clinical Trial.
-
Prognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: a systematic review and meta-analysis.Oncotarget. 2016 Apr 5;7(14):18458-68. doi: 10.18632/oncotarget.7607. Oncotarget. 2016. PMID: 26918342 Free PMC article. Review.
-
The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis.Cancer Invest. 2010 Jul;28(6):661-9. doi: 10.3109/07357901003735634. Cancer Invest. 2010. PMID: 20394501 Review.
Cited by
-
History of myeloid-derived suppressor cells.Nat Rev Cancer. 2013 Oct;13(10):739-52. doi: 10.1038/nrc3581. Nat Rev Cancer. 2013. PMID: 24060865 Free PMC article. Review.
-
FGFR3 silencing by siRNA inhibits invasion of A549 cells.Oncol Lett. 2016 Dec;12(6):4319-4326. doi: 10.3892/ol.2016.5278. Epub 2016 Oct 18. Oncol Lett. 2016. PMID: 28105147 Free PMC article.
-
Prognostic effect of matrix metalloproteinase-9 in patients with resected Non small cell lung cancer.J Cardiothorac Surg. 2015 Mar 27;10:44. doi: 10.1186/s13019-015-0248-3. J Cardiothorac Surg. 2015. PMID: 25888323 Free PMC article.
-
Elevated matrix metalloproteinase-7 expression promotes metastasis in human lung carcinoma.World J Surg Oncol. 2015 Jan 14;13:5. doi: 10.1186/1477-7819-13-5. World J Surg Oncol. 2015. PMID: 25588786 Free PMC article.
-
A multigenic approach to evaluate genetic variants of PLCE1, LXRs, MMPs, TIMP, and CYP genes in gallbladder cancer predisposition.Tumour Biol. 2014 Sep;35(9):8597-606. doi: 10.1007/s13277-014-2094-7. Epub 2014 May 27. Tumour Biol. 2014. PMID: 24863943
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous